Canntab Therapeutics Limited
CTABF · OTC
2/28/2023 | 11/30/2022 | 8/31/2022 | 5/31/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $7 | $10 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $2 | $2 | $2 | $2 |
| Enterprise Value | $3 | $3 | $9 | $11 |
| Revenue | -$0 | $0 | $0 | $0 |
| % Growth | -226% | -54.3% | -2.6% | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | 22.2% | 2.4% | 68.8% | -137.4% |
| EBITDA | -$0 | -$1 | -$0 | -$1 |
| % Margin | 720.3% | -3,519.7% | -298.2% | -2,642.8% |
| Net Income | -$0 | -$1 | -$0 | -$1 |
| % Margin | 1,862.4% | -5,860.7% | -1,214.9% | -3,652.7% |
| EPS Diluted | -0.011 | -0.027 | -0.012 | -0.037 |
| % Growth | 60% | -120.8% | 67.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$1 | -$1 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$1 | -$1 |